Loading...
Loading...
VAXX| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 19.8M |
| Operating I/L | -19.8M |
| Other Income/Expense | 0.5M |
| Interest Income | 0.5M |
| Pretax | -19.3M |
| Income Tax Expense | -0.0M |
| Net Income/Loss | -19.2M |
Vaxxinity, Inc. is a biotechnology company in the United States specializing in developing product candidates for neurology and coronaviruses. Their portfolio includes UB-311 for Alzheimer's disease, UB-312 for Parkinson's disease and other synucleinopathies, an anti-tau product candidate for various neurodegenerative conditions, UB-313 for migraines, anti-PCSK9 for lowering cholesterol, and UB-612 for neutralizing the SARS-CoV-2 virus. The company generates revenue through the development and potential commercialization of these product candidates, targeting neurological disorders and infectious diseases.
